Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6190029 | Bulletin du Cancer | 2015 | 9 Pages |
Abstract
Chemotherapy-induced cardiotoxicity is a major cause of morbidity and mortality in cancer survivor. The most clinically evident and best known cardiotoxicity is the anthracycline adverse effect with heart failure. Many cardiovascular adverse effects appear after cancer therapy: heart congestive failure, myocardial ischemia, hypertension, thromboembolic complications, arrhythmias and conduction disturbances. There are potential strategies to mitigate the risks of cardiac complications for cancer patients with physical examination, echocardiography and electrocardiogram. The management of the cardiotoxicity is variable.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Marie Nelson-Veniard, Jean-Benoit Thambo,